Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

Z. Al-Kadhimi, Z. Gul, M. Abidi, L. G. Lum, A. Deol, W. Chen, H. Jang, C. Ozust, A. Langston, E. Waller, J. Uberti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-Thymocyte globulin (Thymoglobulin Thymo) in combination with tacrolimus and sirolimus (TTS) in 47 patients (pts) for the prevention of acute and chronic GvHD after unrelated AHSCT. The median follow-up was 45.2 months. The cumulative incidence of NIH severe cGvHD at 48 months was 6.4% with no new occurrences past 6 months for the entire follow-up period. The overall cumulative incidence of cGvHD was 44.7%. Out of 20 pts who are alive and disease-free at the last follow-up, only 4 pts continue to need systemic immune suppression. We observed low late NRM with only 3 transplant-related deaths after 6 months post transplant. At 4 years of follow-up, the overall cumulative incidence of NRM and disease relapse was 27.7% and 30.0%, respectively. PFS and overall survival (OS) at 4 years were 42 and 47%. At long term follow-up, TTS was associated with low incidence of severe cGvHD and late NRM.

Original languageEnglish (US)
Pages (from-to)1304-1310
Number of pages7
JournalBone marrow transplantation
Volume52
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Tacrolimus
Sirolimus
Transplants
Mortality
Incidence
Hematopoietic Stem Cells
Antilymphocyte Serum
Rabbits
Morbidity
Recurrence
Survival
thymoglobulin

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. / Al-Kadhimi, Z.; Gul, Z.; Abidi, M.; Lum, L. G.; Deol, A.; Chen, W.; Jang, H.; Ozust, C.; Langston, A.; Waller, E.; Uberti, J.

In: Bone marrow transplantation, Vol. 52, No. 9, 01.09.2017, p. 1304-1310.

Research output: Contribution to journalArticle

Al-Kadhimi, Z, Gul, Z, Abidi, M, Lum, LG, Deol, A, Chen, W, Jang, H, Ozust, C, Langston, A, Waller, E & Uberti, J 2017, 'Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention', Bone marrow transplantation, vol. 52, no. 9, pp. 1304-1310. https://doi.org/10.1038/bmt.2017.95
Al-Kadhimi, Z. ; Gul, Z. ; Abidi, M. ; Lum, L. G. ; Deol, A. ; Chen, W. ; Jang, H. ; Ozust, C. ; Langston, A. ; Waller, E. ; Uberti, J. / Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. In: Bone marrow transplantation. 2017 ; Vol. 52, No. 9. pp. 1304-1310.
@article{292d8bc5104546d285fdaeb41463b2e6,
title = "Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention",
abstract = "Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-Thymocyte globulin (Thymoglobulin Thymo) in combination with tacrolimus and sirolimus (TTS) in 47 patients (pts) for the prevention of acute and chronic GvHD after unrelated AHSCT. The median follow-up was 45.2 months. The cumulative incidence of NIH severe cGvHD at 48 months was 6.4{\%} with no new occurrences past 6 months for the entire follow-up period. The overall cumulative incidence of cGvHD was 44.7{\%}. Out of 20 pts who are alive and disease-free at the last follow-up, only 4 pts continue to need systemic immune suppression. We observed low late NRM with only 3 transplant-related deaths after 6 months post transplant. At 4 years of follow-up, the overall cumulative incidence of NRM and disease relapse was 27.7{\%} and 30.0{\%}, respectively. PFS and overall survival (OS) at 4 years were 42 and 47{\%}. At long term follow-up, TTS was associated with low incidence of severe cGvHD and late NRM.",
author = "Z. Al-Kadhimi and Z. Gul and M. Abidi and Lum, {L. G.} and A. Deol and W. Chen and H. Jang and C. Ozust and A. Langston and E. Waller and J. Uberti",
year = "2017",
month = "9",
day = "1",
doi = "10.1038/bmt.2017.95",
language = "English (US)",
volume = "52",
pages = "1304--1310",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

AU - Al-Kadhimi, Z.

AU - Gul, Z.

AU - Abidi, M.

AU - Lum, L. G.

AU - Deol, A.

AU - Chen, W.

AU - Jang, H.

AU - Ozust, C.

AU - Langston, A.

AU - Waller, E.

AU - Uberti, J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-Thymocyte globulin (Thymoglobulin Thymo) in combination with tacrolimus and sirolimus (TTS) in 47 patients (pts) for the prevention of acute and chronic GvHD after unrelated AHSCT. The median follow-up was 45.2 months. The cumulative incidence of NIH severe cGvHD at 48 months was 6.4% with no new occurrences past 6 months for the entire follow-up period. The overall cumulative incidence of cGvHD was 44.7%. Out of 20 pts who are alive and disease-free at the last follow-up, only 4 pts continue to need systemic immune suppression. We observed low late NRM with only 3 transplant-related deaths after 6 months post transplant. At 4 years of follow-up, the overall cumulative incidence of NRM and disease relapse was 27.7% and 30.0%, respectively. PFS and overall survival (OS) at 4 years were 42 and 47%. At long term follow-up, TTS was associated with low incidence of severe cGvHD and late NRM.

AB - Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-Thymocyte globulin (Thymoglobulin Thymo) in combination with tacrolimus and sirolimus (TTS) in 47 patients (pts) for the prevention of acute and chronic GvHD after unrelated AHSCT. The median follow-up was 45.2 months. The cumulative incidence of NIH severe cGvHD at 48 months was 6.4% with no new occurrences past 6 months for the entire follow-up period. The overall cumulative incidence of cGvHD was 44.7%. Out of 20 pts who are alive and disease-free at the last follow-up, only 4 pts continue to need systemic immune suppression. We observed low late NRM with only 3 transplant-related deaths after 6 months post transplant. At 4 years of follow-up, the overall cumulative incidence of NRM and disease relapse was 27.7% and 30.0%, respectively. PFS and overall survival (OS) at 4 years were 42 and 47%. At long term follow-up, TTS was associated with low incidence of severe cGvHD and late NRM.

UR - http://www.scopus.com/inward/record.url?scp=85028872184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028872184&partnerID=8YFLogxK

U2 - 10.1038/bmt.2017.95

DO - 10.1038/bmt.2017.95

M3 - Article

C2 - 28581472

AN - SCOPUS:85028872184

VL - 52

SP - 1304

EP - 1310

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -